AstraZeneca PLC (FRA:ZEG)
127.95
+0.80 (0.63%)
At close: Jun 6, 2025, 10:00 PM CET
AstraZeneca Employees
AstraZeneca had 94,300 employees as of December 31, 2024. The number of employees increased by 4,400 or 4.89% compared to the previous year.
Employees
94,300
Change (1Y)
4,400
Growth (1Y)
4.89%
Revenue / Employee
€539,442
Profits / Employee
€76,253
Market Cap
198.58B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Rheinmetall AG | 28,539 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Siemens Energy AG | 98,000 |
Siemens Healthineers AG | 72,000 |
AstraZeneca News
- 1 day ago - AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet - Seeking Alpha
- 2 days ago - AstraZeneca’s £1 Billion Cambridge Hub Fuels UK Biotech Surge - ABC Money
- 5 days ago - Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO - CNBC
- 6 days ago - AstraZeneca says Enhertu, Perjeta combo cuts death risk in breast cancer - Seeking Alpha
- 6 days ago - AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment - CNBC
- 6 days ago - How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma - Investor's Business Daily
- 6 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial - Benzinga
- 6 days ago - ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial - Benzinga